RxDoctor Payments Data

Stephen Rittman, MD

Family Medicine · Schaumburg, ILNPI 1104857473

Payments from drug & device makers

$12,197in general payments, 2019–2025

Across 745 payments — averaging $16.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$2K
  • Boehringer Ingelheim$1K
  • Lilly USA, LLC$824
  • Pfizer$756
  • Johnson & Johnson$723
  • plus $5K from 31 others

What the payments were for

  • Food & beverage$12,01098%
  • Education$1872%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,197 in reported general payments places this provider in the 95th percentile of 4,116 family medicine providers in Illinois.

See all family medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$118,858
Medicare patients
344
Services billed
1,601

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol78$83,309
EliquisApixaban69$75,306
OzempicSemaglutide50$75,267
XareltoRivaroxaban48$50,683
JardianceEmpagliflozin27$40,566
TrulicityDulaglutide17$39,737
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$36,043
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr41$22,824
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog23$22,055
JanuviaSitagliptin Phosphate15$20,362
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$10,669
Breo ElliptaFluticasone/Vilanterol11$7,903
Janumet XrSitagliptin Phos/Metformin Hcl12$6,542
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog14$6,523
Stiolto RespimatTiotropium Br/Olodaterol Hcl14$6,513

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere$1,639$93,97890 claims
PfizerEliquis$756$75,30669 claims
Novo NordiskOzempic$656$75,26750 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$674$66,77086 claims
Johnson & JohnsonXarelto$723$50,68348 claims
Boehringer IngelheimJardiance, Stiolto Respimat$1,075$47,07941 claims
Lilly USA, LLCTrulicity$824$39,73717 claims
MerckJanuvia, Janumet Xr$56$26,90427 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,116 family medicine providers in Illinois.

Other family medicine in Schaumburg

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →